CTS: Sorafenib Shows No Advantage in Non-Small-Cell Lung Cancer
It’s three strikes for the oral multikinase inhibitor sorafenib (Nexavar) for treating advanced non-small-cell lung cancer in the ESCAPE trial.An updated analysis of the Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC (ESCAPE) trial failed to show any advantage for sorafenib, researchers said at the Chicago Multidisciplinary Symposium on Thoracic Oncology.
This entry was posted on Tuesday, November 18th, 2008 at 3:11 pm and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.